How have Polynovo shares been performing since leaving the ASX 200?

The medical device company's shares can't seem to catch a break this week.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares are edging 1.15% lower to $1.295 on Tuesday
  • While no company announcements have been made, Polynovo shares were removed from the ASX 200 on Monday
  • The quarterly rebalance forces fund managers to adjust their portfolios to adhere to operating mandates, which in turn can put buying or selling pressure on particular shares

The Polynovo Ltd (ASX: PNV) share price is heading south again today despite the company not releasing any announcements.

Since the start of the week, the medical device company's shares are down 3% to currently trade at $1.295 each.

While down 1.15% today, this isn't the case for the S&P/ASX 200 Index (ASX: XJO) which is 1.59% higher to 6,535 points at the time of writing.

Let's take a look at what is weighing down the Polynovo share price of late.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

What's impacting Polynovo shares?

Besides the recent buying action by the company's board, it has been relatively quiet for Polynovo.

Its last trading update came in early April when management provided a snapshot of the company's third-quarter results.

Since then, Polynovo shares tumbled to a multi-year low of 83.5 cents before rebounding to February 2022 levels.

The share price weakness came off the back of negative investor sentiment across the ASX following fears surrounding a possible recession.

However, added to the mix is the large number of short-sellers on Polynovo's registry.

The latest short position report by the Australian Securities & Investments Commission (ASIC) reveals the level of short interest within companies.

Polynovo remains in the top 10 of short interest ASX stocks, with 10.95% of its shares being shorted by investors.

In case you aren't aware, short-selling is a common trading strategy that aims to profit from the fall in the price of a security. The goal is for an investor to borrow shares then sell them and buy them back at a lower price for a profit.

On top of this, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has fallen by 4.63% in the past week and is down 15% in 2022.

Yet perhaps the biggest selling pressure has come from Polynovo's removal from the S&P/ASX 200 Index (ASX: XJO) which took effect on Monday.

The S&P Dow Jones Indices announced changes in its quarterly rebalance earlier this month.

Polynovo's removal from the ASX 200 means that fund managers must abide by their investing mandate which permits them to only buy shares included in specific indices. It's commonplace that shares can climb or fall after being included in or excluded from a particular index.

Polynovo share price summary

While staging a small rebound from early May onwards, the Polynovo share price is down 15% year-to-date.

When looking at the past 12 months, its shares are deep in the red by 53%.

Based on today's price, Polynovo presides a market capitalisation of about $856 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Healthcare Shares

Historic: Here's why CSL shares are looking very interesting right now

CSL's yield now rivals a big four bank...

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

4DMedical shares jump 11% as investors cheer major US agreement

4DMedical has landed another commercial foothold in the US.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Healthcare Shares

Which ASX healthcare stock could rise over 100% according to Bell Potter?

Let's see what the broker is saying about this stock this week.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These 3 ASX healthcare stocks have been crushed in 2026. They could be set for a comeback

CSL is at a 10-year low. Cochlear has fallen 62%. ResMed is down on fears that proved wrong. Are any…

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Should I buy CSL shares in June?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

A man in a business suit holds his hand up to his mouth as though sharing a secret and gives a sly grin.
Healthcare Shares

After CSL's 60% share price crash, insiders are starting to buy

Insiders are buying after a brutal CSL share price fall.

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

At under $100 each, Cochlear shares look like a bargain: Here's why

Cochlear Ltd (ASX: COH) shares have now crashed 63% for the year-to-date.

Read more »

A doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

3 ASX 200 shares I'd buy for the future of healthcare

Healthcare investing often requires patience, but I think the sector can produce some excellent long-term winners.

Read more »